Wedbush lowered the firm’s price target on Apellis (APLS) to $18 from $20 and keeps a Neutral rating on the shares. Overall, the Q4 report from Apellis was largely as anticipated with the company preannouncing key results in January, the firm notes. Management anticipates flat Syfovre pricing into FY26 and more limited growth. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on APLS: Dis ...

Core Insights - Disc Medicine, Inc. reported financial results for Q4 and full year 2025, highlighting progress in its clinical programs and a strong cash position [1][5][6] Financial Performance - Cash, cash equivalents, and marketable securities totaled approximately $791 million as of December 31, 2025, up from $490 million in 2024, providing a runway into 2029 [6][11] - Research and Development (R&D) expenses increased to $170.6 million in 2025 from $96.7 million in 2024, driven by advancements in clinical studies and increased headcount [11][13] - Selling, General and Administrative (SG&A) expenses rose to $65.4 million in 2025 from $33.0 million in 2024, primarily due to increased headcount and infrastructure development [11][13] - The net loss for 2025 was $212.2 million, compared to a net loss of $109.4 million in 2024, attributed to higher operating costs [11][13] Clinical Developments - The Phase 3 APOLLO study for bitopertin is expected to complete enrollment in March 2026, with topline data anticipated in Q4 2026 [6][7] - Initial data from the Phase 2 study of DISC-0974 in patients with anemia of myelofibrosis (MF) showed meaningful overall anemia responses across all patient subgroups [6][7] - The company is progressing with the Phase 2 study of DISC-3405 in polycythemia vera and has initiated a Phase 1b study in sickle cell disease, with data expected in the second half of 2026 [6][7] Pipeline Overview - Bitopertin is a GlyT1 inhibitor aimed at treating erythropoietic protoporphyria (EPP) [3] - DISC-0974 is an anti-hemojuvelin antibody focused on hepcidin suppression [4] - DISC-3405 is an anti-TMPRSS6 antibody targeting hepcidin induction [4]

THE WOODLANDS, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its fourth quarter 2025 financial results on Thursday, March 5, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company’s website at http ...

Fourth Quarter and Full Year 2025 Financial Results F E B R U A R Y 2 6 , 2 0 2 6 | FINANCIAL | 48% Full-year royalty revenue growth over 2024 | | --- | --- | | Strong financial performance | 42% Full-year core adjusted EPS growth to $8.131 per share | | BUSINESS DEVELOPMENT | Scaling the BD function to capture value from our deep investment pipeline | | Highly productive, rigorous process | ~$1B Deployable capital (including credit facility) | | | Positions us for continued growth and expansion across our ...

Core Viewpoint - Pulmatrix, Inc. is focusing on advancing its proposed merger with Cullgen while also seeking to license or monetize its iSPERSE™ technology and related clinical programs, particularly in the context of its financial results for the year-end and fourth quarter of 2025 [1][2]. Financial Performance - Revenues for the year ended December 31, 2025, decreased to $0 from $7.8 million in 2024, primarily due to the wind down of the PUR1900 program [2]. - Research and development expenses dropped to less than $0.1 million in 2025 from $7.2 million in 2024, attributed to the cessation of the PUR1900 Phase 2b clinical trial and related operational reductions [2]. - General and administrative expenses decreased to $5.1 million in 2025 from $7.8 million in 2024, reflecting lower employment and operational costs [2]. - The total cash and cash equivalents as of December 31, 2025, were $4.1 million, down from $9.5 million in 2024, with expectations to fund operations into the first quarter of 2027 [2]. Proposed Merger with Cullgen - Pulmatrix entered into a merger agreement with Cullgen on November 13, 2024, with subsequent amendments, and is currently awaiting approval from the China Securities Regulatory Commission (CSRC) [1]. - The merger agreement includes a waiver of the "No Solicitation" clause, allowing both companies to explore alternative transactions while pursuing merger approval [1][2]. iSPERSE™ Technology and Clinical Programs - Pulmatrix's iSPERSE™ technology includes approximately 149 granted patents and 48 pending applications, aimed at improving drug delivery for respiratory diseases [1]. - The company is advancing its clinical programs, including PUR3100, which is ready for Phase 2 trials for acute migraine treatment, and PUR1800, which is being developed for chronic obstructive pulmonary disease [1][2]. - PUR1900, an inhaled formulation of itraconazole, is in Phase 3 trials in India, with Pulmatrix receiving 2% royalties on future net sales outside the U.S. [1][2].

Core Insights - Milestone Pharmaceuticals Inc. will present at the TD Cowen 46th Annual Health Care Conference from March 2-4, 2026 [1] - A live webcast of the presentation will be available on March 3 at 9:10 AM EST, with a replay accessible for approximately 90 days [2] Company Overview - Milestone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative cardiovascular medicines for individuals with specific heart conditions [3] - The company's lead product, CARDAMYST™ (etripamil) nasal spray, is an FDA-approved treatment for converting acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults [3] - Etripamil is also under development for treating symptomatic episodic attacks associated with atrial fibrillation with rapid ventricular response (AFib-RVR) [3]

Conference call today at 9:00 am ETQ4 2025 revenues of $112M, +46% vs. Q4 2024 Furoscix® Q4 2025 net sales of $23M, +91% vs. Q4 2024 Afrezza® Q4 2025 net sales of $23M, +25% vs. Q4 2024 2025 full year revenues of $349M, +22% vs. 2024Successfully completed the acquisition of scPharmaceuticals Inc. (scPharma)Program updates: Afrezza pediatric indication PDUFA date May 29, 2026Furoscix ReadyFlow™ Autoinjector PDUFA date July 26, 2026 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) ...

REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Jennifer Fulk as Chief Financial Officer, succeeding James Mackaness, who announced that he will be retiring from the Company by the end of the first quarter. Mr. Mackaness will serve as a consultant to Soleno through the end of the year to ensure a smooth transition. Mrs. Fu ...

Core Insights - Heron Therapeutics reported a 65% year-over-year net revenue growth in its Acute Care franchise, achieving $154.9 million in net revenue for 2025 and providing guidance for 2026 net revenue between $173 million and $183 million, with adjusted EBITDA expected to be between $10 million and $20 million [1][3]. Financial Performance - The Acute Care franchise experienced a revenue growth of 57.3% year-over-year in Q4 2025 and 65.1% for the full year 2025 compared to 2024, indicating strong commercial acceleration [4]. - Total net revenue for 2025 was $154.9 million, up from $144.3 million in 2024, reflecting a 7.4% increase [9]. - For Q4 2025, total net revenue was $40.6 million, slightly down from $40.8 million in Q4 2024, marking a 0.5% decrease [10]. Product Updates - ZYNRELEF, a key product, received a permanent product-specific J-Code (J0668) from CMS, effective October 1, 2025, which streamlines reimbursement processes [7]. - The transition to the Vial Access Needle for ZYNRELEF has been completed, enhancing product handling and sterility in hospitals and surgical centers [7]. - APONVIE, another significant product, was included in the Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting, highlighting its clinical importance [7]. Market Position and Strategy - The CEO emphasized that the company is entering 2026 with strong momentum, driven by strategic decisions that have unlocked the potential of its assets, particularly ZYNRELEF [2]. - The company is focused on expanding demand signals and improving reimbursement clarity, positioning itself for continued market share gains and revenue growth in 2026 and beyond [2]. Oncology Franchise - The Oncology franchise generated over $105 million in net revenue for 2025, despite facing complex market dynamics [8].

Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates NASDAQ:ZLAB | HKEX:9688 © 2026. Zai Lab. All Rights Reserved. This presentation contains forward-looking statements, including statements relating to our strategy and plans; potential of and expectations for our business, commercial products, and pipeline programs; our goals, objectives, and priorities and our expectations under our growth strategy (including our expectations regarding our commercial products and launches, and ...